Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Related to this article
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
HHS Updates National Alzheimer Disease Plan to Prioritize Prevention
2
Psychedelic Trials Reveal Gaps Between Controlled Efficacy and Real-World Readiness
3
Awareness of Alcohol Use Disorder Medication Is Low Among US Adults, Study Finds
4
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
5